Devyser Diagnostics AB (publ) (STO:DVYSR)
Sweden · Delayed Price · Currency is SEK 107.00
-2.00 (-1.83%)
Feb 10, 2026, 5:29 PM CET
Devyser Diagnostics AB Revenue
Devyser Diagnostics AB had revenue of 56.40M SEK in the quarter ending September 30, 2025, with 15.81% growth. This brings the company's revenue in the last twelve months to 242.70M, up 22.51% year-over-year. In the year 2024, Devyser Diagnostics AB had annual revenue of 216.90M with 28.12% growth.
Revenue (ttm)
242.70M
Revenue Growth
+22.51%
P/S Ratio
7.48
Revenue / Employee
2.25M
Employees
108
Market Cap
1.82B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 216.90M | 47.60M | 28.12% |
| Dec 31, 2023 | 169.30M | 42.70M | 33.73% |
| Dec 31, 2022 | 126.60M | 33.12M | 35.43% |
| Dec 31, 2021 | 93.48M | 27.79M | 42.31% |
| Dec 31, 2020 | 65.69M | 1.39M | 2.16% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Getinge AB | 34.97B |
| Swedish Orphan Biovitrum AB | 28.24B |
| Humana AB | 10.08B |
| Sectra AB | 3.47B |
| Camurus AB | 2.35B |
| EQL Pharma AB | 425.75M |
| Carasent AB | 328.99M |
| BioInvent International AB | 244.85M |